Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA4 | P22748 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29636384 | 1.00 | CA1 (0.57) | CA1CA2CA12CA4CA7 | |
| Hydrochloric Acid SCHEMBL30993972 | 0.98 | CA12 (0.55) | CA1CA2CA12CA4CA7 | |
| SCHEMBL6867123 | 0.82 | ALDH1A1 (0.51) | CA1CA2CA12CA4CA7 | |
| SCHEMBL3191755 | 0.82 | MAPT (0.69) | CA1CA2CA12CA4CA7 | |
| SCHEMBL6240378 | 0.82 | APP (0.48) | CA1CA2CA12CA4CA7 | |
| SCHEMBL1639354 | 0.82 | CA1 (0.60) | CA1CA2CA12CA4CA7 | |
| SCHEMBL24271124 | 0.81 | CA1 (0.52) | CA1CA2CA12CA4CA7 | |
| SCHEMBL11765492 | 0.80 | MAPT (0.55) | ALDH1A1MAPTGAARAB9AL3MBTL1 | |
| SCHEMBL5923798 | 0.80 | MAPT (0.67) | CA1CA2CA12CA4CA7 | |
| SCHEMBL7715781 | 0.79 | APP (0.44) | CA1CA2CA12CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 801 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| EP-2593425-B1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | claimed |
| CN-107105667-A | Probe for being imaged Huntington protein | CHDI基金会股份有限公司 | 2017-08-29 | — | — | CN | claimed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | claimed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | claimed |
| EP-2593425-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | Agios Pharmaceuticals, Inc. (US) | 2013-05-22 | — | — | EP | claimed |
| WO-2012009678-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | WO | claimed |
| EP-2079699-A1 | QUINOLINE DERIVATIVES | Envivo Pharmaceuticals, Inc. (US) | 2009-07-22 | — | — | EP | claimed |
| WO-2008014602-A1 | QUINOLINE DERIVATIVES | ENVIVO PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | WO | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| US-6984673-B2 | Dental cement composition | KURARAY CO., LTD. (JP) | 2006-01-10 | — | — | US | claimed |
| EP-0717739-B1 | 1,4-Benzodioxane derivatives having affinity for D2 receptors and utility in the treatment of psychoses | KNOLL AG (DE) | 2000-03-29 | — | — | EP | claimed |
| CN-122074072-A | Novel and cost-effective polycondensation of 2-methoxymethyl-p-phenylenediamine | 威娜德国有限责任公司 | 2026-05-22 | — | — | CN | disclosed |
| CN-120987794-B | N-p-hydroxyphenyl-N-methyl-2-acetyl acrylamide compound, and preparation method and application thereof | 中国农业大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-4060544-A | COUPLERS | GAF CORPORATION (US) | 1977-11-29 | — | — | US | disclosed |
| US-4039524-A | Keto-amido containing phenylazo benzothiazole dyestuffs | GAF CORPORATION (US) | 1977-08-02 | — | — | US | disclosed |
| US-4021471-A | Formamidines useful as ultraviolet light absorbers | GIVAUDAN CORPORATION (US) | 1977-05-03 | — | — | US | disclosed |
| US-3931145-A | POLYESTER | GAF CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | GNRHR, GHRHR, FSHR | CA1 1710/4885CA2 468/4885CA12 375/4885 |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | CA1 1632/4885CA2 1914/4885CA12 1118/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | CA1 1635/4885CA2 551/4885CA12 2116/4885 |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | CA1 1632/4885CA2 1914/4885CA12 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.